Skip to main content
B

BIONIME CORPORATION — Investor Relations & Filings

Ticker · 4737 TW Manufacturing
Open in API
Filings indexed 1,731 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country TW Taiwan
Listing TW 4737

About BIONIME CORPORATION

https://www.bionime.com

Bionime Corporation is a biotechnology firm specializing in the research, design, and manufacturing of comprehensive blood glucose management systems. The company develops high-precision monitoring solutions for both personal home use and professional medical environments, including Blood Glucose Meters (BGM), Continuous Glucose Monitoring Systems (CGM), and Point-of-Care Testing (POCT). Under its proprietary brand, RIGHTEST, Bionime integrates medical, chemical, electronic, and precision machinery expertise to deliver products that rival international standards. A core component of its offering is a cloud-based management ecosystem powered by IoT digital solutions, which synchronizes medical data with patient care services. With over 480 core patents in CGM technology and a commitment to Industry 4.0 smart production, Bionime focuses on enhancing diabetes care through technical innovation and a human-centered approach to health monitoring.

Recent filings

Filing Released Lang Actions
公告本公司「瑞特安活2連續葡萄糖監測系統 (RIGHTEST iFree2 CGM)」取得衛生福利部食藥署 (TFDA)核發第二等級醫療器材許可證核准通知
Regulatory Filings Classification · 1% confidence The document is a short corporate announcement posted on the public information observation station in Taiwan, notifying the market that the company’s medical device has received regulatory approval from the TFDA. It is not a financial report (Annual, Interim, Earnings, etc.), nor a board change, dividend, share transaction, or other specific category. It serves as a general regulatory material-event announcement and thus falls under the fallback category of Regulatory Filings (RNS).
2026-04-29 Chinese
115年3月背書保證與資金貸與
Regulatory Filings Classification · 1% confidence The document is a brief tabular disclosure from Taiwan’s market observation post (“公開資訊觀測站”) detailing the company’s and subsidiaries’ month-end balances of loans and guarantees. It is not an annual or interim report, audit, dividend notice, or any other specific category but a routine regulatory disclosure. This falls under the general Regulatory Filings category (RNS).
2026-04-10 Chinese
115年3月營業收入
Regulatory Filings Classification · 0% confidence The provided text is clearly an error/access page and contains no substantive financial or corporate disclosure content. It does not match any specific filing type definitions. Therefore it defaults to the generic regulatory filings fallback (RNS).
2026-04-10 Chinese
115年04月僑外投資持股
Share Issue/Capital Change Classification · 1% confidence The document is a mandatory disclosure form from the Taiwan Public Information Observatory titled “Overseas and Mainland China Investors Investment Shareholding Statistics.” It shows the reason for change as “cash capital increase” (現金增資) and details share counts before and after the capital increase, plus total issued shares. This corresponds to an announcement regarding a new share issue / capital change.
2026-04-09 Chinese
115年4月變更登記
Share Issue/Capital Change Classification · 1% confidence The document is a detailed breakdown of the company’s share capital structure, including par value, authorized vs. paid‐in capital, and historical capital increases/decreases (cash capital increase, capital reserve conversion, earnings conversion, reduction, etc.). This aligns with a share issue/capital change announcement rather than a full financial report or earnings release. Therefore, it falls under the Share Issue/Capital Change category (SHA).
2026-04-08 Chinese
公司基本資料
Regulatory Filings Classification · 1% confidence The document is a standard statutory disclosure of basic corporate information (company name, address, stock code, management, auditors, share capital, listing dates, IR contacts, etc.) filed via Taiwan’s public information platform (公開資訊觀測站). It does not present financial results or an earnings release (ER/IR/10-K), nor is it a meeting presentation, proxy solicitation, dividend notice, capital change, board change, M&A, or legal notice. It is not announcing publication of another report but is itself a regulatory data sheet for investor information. This falls under the fallback category for miscellaneous regulatory filings that don’t fit any specific type.
2026-04-08 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.